AADI vs. MDWD, CRDF, IMAB, PRQR, SOPH, SCPH, MNPR, YMAB, CRGX, and GNFT
Should you be buying Aadi Bioscience stock or one of its competitors? The main competitors of Aadi Bioscience include MediWound (MDWD), Cardiff Oncology (CRDF), I-Mab (IMAB), ProQR Therapeutics (PRQR), SOPHiA GENETICS (SOPH), scPharmaceuticals (SCPH), Monopar Therapeutics (MNPR), Y-mAbs Therapeutics (YMAB), CARGO Therapeutics (CRGX), and GENFIT (GNFT). These companies are all part of the "pharmaceutical products" industry.
Aadi Bioscience vs. Its Competitors
Aadi Bioscience (NASDAQ:AADI) and MediWound (NASDAQ:MDWD) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, earnings, dividends, analyst recommendations, institutional ownership and valuation.
MediWound has a net margin of -110.45% compared to Aadi Bioscience's net margin of -246.06%. Aadi Bioscience's return on equity of -71.87% beat MediWound's return on equity.
MediWound has lower revenue, but higher earnings than Aadi Bioscience. MediWound is trading at a lower price-to-earnings ratio than Aadi Bioscience, indicating that it is currently the more affordable of the two stocks.
In the previous week, Aadi Bioscience and Aadi Bioscience both had 1 articles in the media. Aadi Bioscience's average media sentiment score of 0.00 equaled MediWound'saverage media sentiment score.
Aadi Bioscience has a beta of 0.68, meaning that its share price is 32% less volatile than the S&P 500. Comparatively, MediWound has a beta of 0.32, meaning that its share price is 68% less volatile than the S&P 500.
52.1% of Aadi Bioscience shares are held by institutional investors. Comparatively, 46.8% of MediWound shares are held by institutional investors. 37.3% of Aadi Bioscience shares are held by insiders. Comparatively, 9.2% of MediWound shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Aadi Bioscience currently has a consensus target price of $1.67, indicating a potential downside of 16.25%. MediWound has a consensus target price of $31.80, indicating a potential upside of 63.33%. Given MediWound's stronger consensus rating and higher probable upside, analysts clearly believe MediWound is more favorable than Aadi Bioscience.
Summary
MediWound beats Aadi Bioscience on 8 of the 14 factors compared between the two stocks.
Get Aadi Bioscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for AADI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding AADI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aadi Bioscience Competitors List
Related Companies and Tools
This page (NASDAQ:AADI) was last updated on 7/6/2025 by MarketBeat.com Staff
